Inveterate deal-maker and former six-term congressman Jim Greenwood believes the biopharma industry should engage on drug pricing legislation with the newly Democratic-controlled US Congress and President-elect Joe Biden and perhaps concede to price inflation rebates in Medicare to avoid worse policies like international reference pricing.
Making The Case For A Legislative Deal On Drug Pricing
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.
